Product logins

Find logins to all Clarivate products below.


Swarali Tadwalkar

Principal Consultant

Swarali has over 9 years of experience in providing consultancy support for the design and implementation of market sizing, epidemiology and real-world studies. Swarali has led multiple projects across a wide array of therapy areas, including rare diseases, oncology, and metabolic disorders. Swarali acts as a project lead/manager for projects involving data collation, epidemiology analysis, market sizing strategies, data forecasting and deriving insights from various real-world data assets. She supports clients in various aspects, such as developing strategies to understand disease market, meeting preparation and development of evidence dossiers/briefing books for FDA/EMA submissions. Throughout her career, she has developed a strong interest in tackling data challenges for analyzing complex disease indications and deriving robust insights especially for rare diseases.

Swarali has presented epidemiology forecasts and results from real-world data studies at various conferences, including, the World Cancer Congress and the Indian Cancer Congress. She holds an MPH degree from the University of South Florida, Tampa specializing in Epidemiology and Biostatistics and a BE in Biotechnology from the University of Mumbai.

Latest news

News May 13, 2026
Clarivate Identifies Five Medtech Trends Set to Redefine Growth Opportunities in 2026

New Medtech Trends to Watch report highlights market shifts, care delivery changes and competitive dynamics poised to reshape medtech strategy London, U.K.  May 13, 2026. Clarivate Plc (NYSE:CLVT), a leading…

News May 6, 2026
Clarivate launches Web of Science Research Intelligence

AI-native research intelligence platform for research funding, strategy and impact now available globally to institutions LONDON, UK — May 6, 2026: Clarivate Plc (NYSE: CLVT), a leading global provider of…

News April 29, 2026
Clarivate Reports First Quarter 2026 Results

— Value Creation Plan delivering accelerated organic revenue growth — — Utilized solid free cash flow generation to deleverage — — Reaffirms 2026 financial outlook — London, UK — April…

Related resources

How the Inflation Reduction Act could impact access to more convenient therapeutics How the Inflation Reduction Act could impact access to more convenient therapeutics
Blog February 17, 2026
How the Inflation Reduction Act could impact access to more convenient therapeutics
Biopharma Biotech Commercialization Consulting Resource Center FDA HMO Insurance Launch Managed care Market Access North America Payer Pharma pricing Route of administration U.S.
Managing uncertainty for medicine in Washington Managing uncertainty for medicine in Washington
Blog May 15, 2025
Managing uncertainty for medicine in Washington
Clinical research Early drug development research Market Access Pharma Portfolio strategy Research Research and development Research commercialization Research evaluation and management
Navigating uncertainty: What’s keeping healthcare execs up at night in this new era Navigating uncertainty: What’s keeping healthcare execs up at night in this new era
Blog April 2, 2025
Navigating uncertainty: What’s keeping healthcare execs up at night in this new era
Market Access Pharma Portfolio strategy Regulatory Research commercialization
Five Medtech Trends to Watch in 2025 Five Medtech Trends to Watch in 2025
Blog February 11, 2025
Five Medtech Trends to Watch in 2025
Medical technology Medtech Medtech Resource Center